IN THIS ISSUE:
New Drug Treatment for Alzheimers
Reflections from the President
A Disaster Plan for Our Times
From the Dean & CEO
Medical Center Expanding
Book and Photo Exhibit: Remarkable Plastic Surgery videos
NIH & Sackler Forge Partnership
High Blood Sugar Levels Associated with Memory Loss
Researchers Identify a Potential Marker for Melanoma Recurrence
Ways to Use bone Marrow Stem Cells as New Diabetes Treatment
State of-the-Art CT Scanner Installed Near ER
Department of Nursing Applies for Magnet Recognition Award
Medical Center Celebrate s First Anniversary of Service Standards
Trustee Corner
Campus Metrics
Honors, Appointments, Promotions
 

NYU Study Shows Drug Can Treat Late Stages of Alzheimer’s

School of Medicine researchers Barry Reisberg, M.D., and Steven Ferris, Ph.D., led an important multicenter study showing that a drug that quashes the activity of a key brain chemical slows the mental and physical deterioration of patients with moderate to severe Alzheimer’s disease. The new study, published in the April 3 issue of the New England Journal of Medicine, involved 32 medical centers nationwide and enrolled 252 patients.

The drug, memantine, is the first effective treatment for patients in the later stages of Alzheimer’s disease, says Dr. Reisberg, Professor of Psychiatry and Clinical Director of the William and Sylvia Silberstein Aging and Dementia Research and Treatment Center. Dr. Ferris is the center’s Executive Director and the Gerald J. and Dorothy R. Friedman Professor of the Alzheimer’s Disease Center.

“These patients seem to be declining much less, about half as much as ordinarily expected, over a six-month period,” says Dr. Reisberg. “This medication slows down the otherwise inexorable progress of Alzheimer’s, and it is remarkably free of side effects. These are very impressive results. It looks like this drug really will have an impact on this disease.”

Full Story>>


Dr. Steven Ferris (left) and Dr. Barry Reisberg led an important study assessing the effects of a drug on the later stages of Alzheimer’s disease.

A Disaster Plan for Our Times: Medical Center Prepares for Terrorist Threats

While most of us prefer not to dwell on the prospect of another terrorist attack in New York City, a group of dedicated medical professionals and administrators in the Medical Center community are keenly aware that disaster could strike again.

Full Story>>

A Reflection From the President
A Q&A W

In February of this year, Theresa A. Bischoff, President of NYU Hospitals Center, announced that, after nearly 20 years at NYU Medical Center, she would step down from her post at the end of 2003. Dean and CEO Robert M. Glickman, M.D., followed Ms. Bischoff’s announcement with one of his own, citing her accomplishments and long service with warm praise.

What she knows about academic medical centers and healthcare, Ms. Bischoff recalls, she learned mainly at NYU. Before coming here, she was a finance executive with a pharmaceutical company. She began her career at the Medical Center as director of accounting services, but made a point of visiting department heads .

Full Story >>

 

NYU School of Medicine
© 2002 New York University
Ethics and Disclaimer
NYU Medical Center

School of Medicine Web Info